Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

NCT05694312 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Autoimmune Hemolytic Anemia
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Monoclonal B-Cell Lymphocytosis CLL-Type

Interventions

DRUG: Ibrutinib 420 mg

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto